See the DrugPatentWatch profile for Belimumab
Belimumab, sold under the brand name Benlysta, is a medication used to treat active systemic lupus erythematosus (SLE) [1]. While it offers therapeutic benefits, patients and healthcare providers should be aware of potential side effects [1].
What are the common side effects of belimumab?
The most frequently reported side effects associated with belimumab treatment include [1]:
* Nausea
* Diarrhea
* Fever
* Rash
* Low white blood cell counts (leukopenia)
* Insomnia
* Headache
* Depression
* Infusion reactions
Are there serious risks associated with belimumab?
Serious side effects can occur with belimumab, requiring prompt medical attention. These include [1]:
* Serious infections: Belimumab can increase the risk of developing serious bacterial, fungal, or viral infections. Patients should inform their doctor if they experience symptoms of infection such as fever, chills, cough, or sore throat [1].
* Anaphylaxis and hypersensitivity reactions: Severe allergic reactions can occur during or shortly after belimumab administration. Symptoms may include hives, difficulty breathing, swelling of the face or throat, and dizziness. This risk is particularly relevant during infusion [1].
* Psychiatric events: Depression, suicidal thoughts, and other psychiatric issues have been reported. Patients or their caregivers should monitor for new or worsening symptoms of depression, anxiety, or suicidal ideation [1].
* Progressive multifocal leukoencephalopathy (PML): Although rare, PML is a serious brain infection that has been observed in patients treated with immunosuppressants, including belimumab. Symptoms can vary and may include weakness on one side of the body, visual disturbances, and changes in thinking ability [1].
* Malignancy: As with other immunosuppressive agents, there may be an increased risk of developing certain types of cancer [1].
What kind of infusion reactions can happen?
Infusion reactions are a potential concern when receiving belimumab, typically occurring during or shortly after administration [1]. These reactions can include symptoms such as fever, rash, itching, and changes in blood pressure or heart rate [1]. Healthcare providers monitor patients closely during and after infusions to manage these reactions [1].
When does belimumab patent exclusivity expire?
Information regarding belimumab's patent exclusivity expiration can be found through resources like DrugPatentWatch.com [2]. Patent expiry dates are crucial for understanding when generic versions of a drug might become available [2].
How does belimumab work?
Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor. By binding to BLyS, belimumab inhibits its activity, which is believed to play a role in the survival and differentiation of B cells involved in SLE pathogenesis [1].
Sources:
[1] https://www.benlysta.com/
[2] https://drugpatentwatch.com/